Seek Returns

PFE vs. VTRS: Pfizer vs. Viatris Stock Comparison

How do Pfizer (PFE) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Pfizer (PFE) and Viatris (VTRS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Pfizer (PFE) and Viatris (VTRS)
Profile ItemPFEVTRS
NamePfizer Inc.Viatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization167.52 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateJune 1, 1972March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

PFE
VTRS
GSPC
Loading price history…
Pfizer (PFE) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Pfizer (PFE) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Pfizer (PFE) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Pfizer (PFE) and Viatris (VTRS)
MetricPFEVTRS
Total Return (1Y)28.65%108.98%
Total Return (3Y, Annualized)6.41%36.75%
Total Return (5Y, Annualized)-3.98%11.59%

Risk Profile

Drawdown History

PFE
VTRS
GSPC
Loading price history…
Pfizer (PFE) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Pfizer (PFE) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Pfizer (PFE) and Viatris (VTRS)
MetricPFEVTRS
Volatility (1Y, Annualized)21.72%32.53%
Beta (5Y)0.350.86
Max Drawdown (5Y)-58.96%-45.69%
Avg. Volume (3M)33.67M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
PFE and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Pfizer (PFE) and Viatris (VTRS)
MetricPFEVTRS
Sharpe Ratio (1Y)1.123.22
Sortino Ratio (1Y)1.735.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Pfizer (PFE) reports 4.47%, ranking against industry peers normally.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max
109.18%
Q3
6.23%
PFE
4.47%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Pfizer (PFE) reports 6.34%, ranking against industry peers normally.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max
18.05%
PFE
6.34%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Pfizer (PFE) at 33.38% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max
83.12%
PFE
33.38%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Pfizer (PFE) and Viatris (VTRS)
MetricPFEVTRS
ROE (TTM)4.47%-4.21%
ROA (TTM)5.59%2.91%
Net Margin (TTM)6.34%-4.13%
Operating Margin (TTM)33.38%13.85%
Gross Margin (TTM)74.90%41.13%

Growth

Revenue Growth

Both Pfizer (PFE) at -1.65% and Viatris (VTRS) at -2.98% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Pfizer (PFE) and Viatris (VTRS)
MetricPFEVTRS
Revenue Growth (YoY)-1.65%-2.98%
Revenue Growth (3Y CAGR)-14.80%-4.20%
EPS Growth (YoY)-3.55%--
EPS Growth (3Y CAGR)-37.12%--

Financial Strength

Current Ratio (MRQ)

Both Pfizer (PFE) at 1.42 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
PFE
1.42
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Pfizer (PFE) at 0.71 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max
1.42
PFE
0.71
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Pfizer (PFE) and Viatris (VTRS)
MetricPFEVTRS
Current Ratio (MRQ)1.421.55
Debt / Equity (MRQ)0.710.99
Net Debt / EBITDA1.972.64

Dividends

Dividend Yield (TTM)

Both Pfizer (PFE) at 7.30% and Viatris (VTRS) at 2.53% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE
7.30%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Pfizer (PFE) at 245.71% and Viatris (VTRS) at 960.00% report payout ratio above 100%, meaning dividends exceeded current-period earnings on both sides.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE
245.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Pfizer (PFE) and Viatris (VTRS)
MetricPFEVTRS
Dividend Yield (TTM)7.30%2.53%
Dividend Payout Ratio (TTM)245.71%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Pfizer (PFE) trades at 41.99 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max
85.34
Q3
43.46
PFE
41.99
Median
26.69
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; PFE is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Both Pfizer (PFE) at 2.63 and Viatris (VTRS) at 1.55 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
PFE
2.63
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Pfizer (PFE) at 1.88 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max
13.53
Q3
6.54
Median
3.25
PFE
1.88
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Pfizer (PFE) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Pfizer (PFE) and Viatris (VTRS)
MetricPFEVTRS
P/E Ratio (TTM)41.99--
P/S Ratio (TTM)2.631.55
P/B Ratio (MRQ)1.881.67
Free Cash Flow Yield (TTM)7.76%13.84%